Format

Send to

Choose Destination
J Obstet Gynaecol Can. 2007 Jul;29(7 Suppl 2):S1. doi: 10.1016/S1701-2163(16)32573-7.

Canadian Consensus Guideline on Continuous and Extended Hormonal Contraception, 2007.

Author information

1
Vancouver BC.
2
Quebec City QC.
3
Ottawa ON.
4
Toronto ON.
5
Quispamsis NB.
6
Kingston ON.
7
Montreal QC.
8
Markham ON.
9
Public Health Agency of Canada, Ottawa ON.

Abstract

OBJECTIVE:

To serve as a guideline for health care providers on the use of continuous and extended combined hormonal contraception regimens, to prevent pregnancy, and to delay menses that affect health-related quality of life.

OPTIONS:

All combined hormonal contraceptive methods available in Canada that may be used in a continuous or extended regimen are reviewed, and the implications are discussed.

OUTCOMES:

Efficacy of cited regimens and assessment of their side effects, patient safety, medical usage and non-contraceptive benefits, cost-effectiveness, and availability in Canada. Indications for patient counselling are also provided.

EVIDENCE:

Medline, PubMed, and Cochrane Database were searched for articles published in English between 1977 and May 2007. Relevant publications and position papers from appropriate reproductive health and family planning organizations were also reviewed.

VALUES:

The quality of evidence is rated using the criteria described by the Canadian Task Force on Preventive Health Care (Table 1).

BENEFITS, HARMS, AND COSTS:

The guideline is intended to help reduce unintended pregnancies and improve health-related quality of life in women who find their menses problematic. Increased awareness and empowerment of women, their partners, and health care professionals will improve their ability to make appropriate choices between continuous or extended and cyclic usage of these regimens.

SPONSORS:

The development of this guideline has been supported by unrestricted grants from Bayer HealthCare Pharmaceuticals, Janssen Ortho, Organon Canada Ltd., Paladin Labs Inc., Pfizer Canada Inc., and Wyeth Pharmaceuticals.

PMID:
17761109
DOI:
10.1016/S1701-2163(16)32573-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center